[Attention deficit hyperactivity disorder: pharmacotherapy in special situations]

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Attention deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder.
• ADHD often presents with neurocognitive dysfunction and comorbid conditions in a significant portion of children.
• Pharmacotherapy for ADHD should ideally address core symptoms and co-occurring disorders.

Purpose of the Study:

• To review the efficacy of atomoxetine hydrochloride in managing ADHD.
• To explore atomoxetine's role in treating ADHD comorbidities such as destructive behavior, anxiety, and sleep disorders.
• To assess atomoxetine's impact on neurocognitive deficits, including sluggish cognitive tempo and executive functioning.

Main Methods:

• Literature review of studies on atomoxetine for ADHD and its comorbidities.
• Analysis of clinical data regarding atomoxetine's effects on executive functioning and cognitive tempo.
• Examination of dosing strategies and adverse event profiles associated with atomoxetine treatment.

Main Results:

• Atomoxetine demonstrates a positive effect on both ADHD symptoms and various comorbid conditions.
• The drug has shown benefits in improving sluggish cognitive tempo and executive functioning.
• Optimal dosing and management strategies can minimize adverse events.

Conclusions:

• Atomoxetine hydrochloride is a valuable therapeutic option for ADHD, particularly when comorbidities are present.
• It offers a dual benefit by addressing core ADHD symptoms and associated neurocognitive deficits.
• Careful dosing and monitoring are essential for maximizing efficacy and patient safety.